1st Department of Pediatrics, Pediatric Immunology and Rheumatology Referral Center, Hippokration General Hospital, Aristotle University of Thessaloniki, 49 Konstantinoupoleos St., 54642 Thessaloniki, Greece.
Vaccine. 2010 Jul 12;28(31):5109-13. doi: 10.1016/j.vaccine.2010.03.080. Epub 2010 May 12.
Our aim was to study the effect of anti-TNF treatment on immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Thirty-one children (mean age:12.9+/-4.6 years) treated with anti-TNFs plus Disease Modifying Anti-Rheumatic Drugs (DMARDs) and 32 age-matched children treated only with DMARDs were vaccinated with two doses of PCV7. After the first vaccine dose geometric mean titers (GMTs) were significantly increased for all vaccine serotypes (p<0.0001) in both groups and were found to be protective (>0.35microg/ml) in 87-100% of all children, depending on the serotype. Children receiving anti-TNFs achieved a significantly lower GMTs against serotypes 4, 14 and 23F (p<0.05). A >or=4-fold increase of the baseline titers to >or=5 vaccine serotypes was observed in 50% and 75% of the anti-TNF and control patients, respectively (p=0.0697). No patient developed vaccine-associated serious adverse events or disease flares.
我们的目的是研究抗 TNF 治疗对幼年特发性关节炎儿童中 7 价结合型肺炎球菌疫苗免疫原性和安全性的影响。31 名接受抗 TNF 联合疾病修饰抗风湿药物（DMARDs）治疗的儿童（平均年龄：12.9±4.6 岁）和 32 名仅接受 DMARDs 治疗的年龄匹配儿童接受了两剂 PCV7 疫苗接种。第一剂疫苗接种后，两组所有疫苗血清型的几何平均滴度（GMT）均显著升高（p<0.0001），根据血清型的不同，所有儿童中有 87-100%的GMT 被认为具有保护作用（>0.35μg/ml）。接受抗 TNF 治疗的儿童针对血清型 4、14 和 23F 的 GMT 显著降低（p<0.05）。分别有 50%和 75%的抗 TNF 和对照组患者的基线滴度增加了 4 倍以上，达到了 >or=5 种疫苗血清型（p=0.0697）。没有患者发生与疫苗相关的严重不良事件或疾病加重。
